This is a pre-announcement of the upcoming competition. The tendering will be a joint procurement for the cooperation area of Eastern Finland (North Savo Welfare Area, South Savo Welfare Area, North Karelia Welfare Area, Central Finland Welfare Area). The object of the procurement is medicinal products and similar products. This acquisition is a complementary purchase of medicines for the Eastern Finland cooperation area. The estimated value of the procurement is approximately EUR 34 million. According to a preliminary estimate, the tender will be published in October 2024 (this is an estimate and is subject to change). The products to be procured are subject to fixed-term contracts. The following ATC groups will be preliminarily included in the future competitive tendering, and according to the preliminary contract periods: For the groups listed below, the actual contract period is three (3) years, for the period 1.4.2025-31.3.2028 and in addition one (1) option year for the period: 1.4.2028-31.3.2029 N01AB HALOGENOID HIILIVEDIT (Inhalation anaesthetics) Competitive tendering of the whole group (including sevoflurane and desflurane) V07AY LUUSEMENTS (Other non-therapeutic auxiliary products) This is a competitive tendering of antibiotic-containing bone cements used in hip, knee and shoulder replacement surgery and trauma patient surgeries. The tendering procedure does not apply to bone cements used in back operations. (In this section, the wellbeing services county of Central Finland is not included in the procurement) Å01 Cytostatic-loaded embolisation microparticles in chemo-embolisation treatment In this section, the contractors Pohjois-Savo wellbeing services county and Etelä-Savo wellbeing services county in the groups listed below are included in the actual contract period of one (1) year, for the period: 1.4.2025-31.3.2026 plus one (1) option year, for the period: 1.4.2026-31.3.2027 B01AB04 Dalteparin, HERARINE GROUP (Small molecular weight heparin) B01AB05 Enoxaparin, HEPARINE GROUP (Small molecular weight heparin) B01AB10 Tinzaparin, HEPARINE GROUP (Small molecular weight heparin) J06BC03 Betslotoxumab, ANTIBACTECTED MONOCLOnal EQUIPMENTS L01F MONOCLOnal EQUIPMENTS and CONTRACTING MEDICAL PRODUCTS L01FY02 Nivolumab and relatlimab L04AA CELECTIVE IMMUNOSUPPRESSANTS (NOTE! ATC codes have changed) The entire group will be tendered, except for the tendering: L04AA03- L04AA19 groups For the sake of clarity, it is stated that the tendering process does NOT include: L04AA03 (ATC code remains the same), Antilymphocyte immunoglobulin inf.kons, 50 mg/1 ml L04AA04 (ATC code remains the same), Antitymocyte immunoglobulin inf.ka/liu, 5 mg/1 ml L04AA06 (ATC code remains the same), Mycophenolic acid L04AA10 ==> L04AH01, Sirolimus L04AA13 ==> L04AK01, Leflunomide L04AA18 ==> L04AH02, Everolimus L04AA23 ==> L04AG03, Natalizumab L04AA24 (ATC code remains the same), Abatacept L04AA25 ==> L04AJ01, Eculizumab L04AA26 ==> L04AG04, Belimumab L04AA27 ==> L04AE01, Fingolimod L04AA29 ==> L04AF01, Tofacitinib L04AA31 ==> L04AK02, Teriflunomide L04AA32 (ATC code remains the same) Apremilast L04AA33 ===> L04AG05, Vedolizumab L04AA34 ===> L04AG06, Alemtutsumab L04AA36 ==> L04AG, Ocrelizumab L04AA37 ===> L04AF02, Baricitinib L04AA40 (ATC code remains the same), Cladribine L04AA41 (ATC code remains the same), Imlifidase L04AA42 ==> L04AE03, Siponimode L04AA43 ==> L04AJ02 Ravulizumab L04AA44 ==> L04AF03, Upadacitinib L04AA45 ==> L04AF04, Filgotinib L04AA50 ==> L04AE04, Ponesimode L04AA51 ===> L04AG11, Anifrolumab L04AA52 ==> L04AG12, Ofatumumab L04AA54 ==> L04AJ03, Pegcetacoplane L04AA55 ==> L04AJ04, Sutimlimab L04AA56 ===> L04AF07, Deucravasitinib L04AA59 ===>04AJ05, Avakopane L04AB TUUMORINE CROOSITES ALFAN EXPRESSIONS Competitive tendering for the whole group L04AC INTERLEUKINE EXPRESSIONS Competitive tendering for the whole group M03AC11 Sister Crater, OTHER KVATERNARIARY AMMONIUM CONDITIONS N01BB58 Articaine, combination products, AMIDIT R03AL02 Salbutamol and ipratropium bromide, ADRENERGICAL MEDICINES AND ANTICOLINERGIES COMMON.COMMON.COMMEND. S01J DIAGNOSTICAL INGREDIENTS S01K CHURGICAL ASSISTANCES S01LA06 Brolucizumab, MEDICINES TO BE USED FOR A NEW CONSUMPTION V03AB35 Sugammadeksi V04CL ALLERGIATESTS S01LA06 Brolucizumab, MEDICINES TO BE USED FOR A NEW CONSUMPTION V03AB35 Sugammadeksi V04CL ALLERGIATESTS The whole group (in this section, the Central Finland Welfare Region is not involved in the procurement) All the above information is estimates and preliminary information, which may change. A more detailed description of the products to be put out to tender and those to be excluded from the procurement will be included in the tender documents. This announcement is a preview of the upcoming competition.
Text automatically translated in your browsing language
Automatically translated
